Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
-
Published:2024-10
Issue:5
Volume:22
Page:102123
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Bellmunt JoaquimORCID,
Maroto Pablo,
Bonfill Teresa,
Vazquez Federico,
Perez-Gracia Jose Luis,
Juanpere Nuria,
Hernandez-Prat AnnaORCID,
Hernandez-Llodra Silvia,
Rovira AnaORCID,
Juan OscarORCID,
Rodriguez-Vida Alejo
Reference36 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up ☆;Powles;Ann Oncol,2022
3. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020
4. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study;Balar;Lancet Oncol,2017
5. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial;Sharma;Lancet Oncol,2017